CTMX

CytomX TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$7.00

+121.5% vs current

Most likely

Base case

45%

Probability

Target price

$4.80

+51.9% vs current

B-

Bear case

25%

Probability

Target price

$2.60

-17.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-05

AI commentary

Near-term tone is constructive but still monitoring-style. Primary company materials support a credible milestone calendar, and recent trusted-news attention centered on favorable Varseta-M data and the subsequent financing. Still, there is no usable social packet coverage, analyst revision detail is sparse, and low coverage means the thesis should lean more on company-confirmed milestones than on sentiment extrapolation [#PR-2026-03-16] [#PR-2026-04-30] [#8-K-2026-03-19].

RankAlpha Sentiment Codex - 2026-05-05

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07catalystQ1 2026 financial results and business update on May 7High impact

CytomX said it will report first-quarter 2026 financial results after market close on May 7, 2026, with a same-day webcast; this is the nearest company-set checkpoint for updated cash use, offering impact, and program pacing after the March financing [#PR-2026-04-30] [#8-K-2026-03-19].

2026-07-15eventMid-2026 FDA alignment on Varseta-M registrational pathHigh impact

Management said its top 2026 priority is to align with the FDA on a potential registrational study design for Varseta-M in late-line colorectal cancer, making regulatory feedback the most important forward de-risking event for the lead asset [#PR-2026-03-16].

2026-12-15catalystLate-2026 CX-801 plus KEYTRUDA initial combination dataHigh impact

CytomX guided to initial clinical data by the end of 2026 for CX-801 in combination with KEYTRUDA in advanced melanoma, giving the company a second meaningful clinical readout beyond Varseta-M if enrollment and dose escalation stay on track [#PR-2026-03-16] [#PR-2026-01-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-05 • Updated nightlySource: Internal modelMethodology